Targeting DNA Repair Defects in Prostate Cancer: The Role of PARP Inhibitors

Get up to date on the use of newly approved and emerging PARP inhibitors for the treatment of patients with metastatic CRPC and DNA repair defects. Includes a case study!
Celestia Higano Headshot
Celestia S. Higano, MD, FACP
Charles J. Ryan, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 744 KB
Released: July 9, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Pfizer, Inc.

Related Content

Focused slideset from experts on the use of radium-223 and PSMA lutetium in the treatment of metastatic castration-resistant prostate cancer, from Clinical Care Options (CCO)

Chris Parker, MD Bertrand Tombal, MD, PhD Released: July 20, 2021

On-demand webcast on PARP inhibitor combination therapies in prostate cancer featuring 3 faculty experts presented by Clinical Care Options (CCO)

Charles J. Ryan, MD
Program Director
person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 7, 2021 Expired: July 6, 2022

Dr. Charles J. Ryan discusses the rationale and evidence for PARP inhibitor combinations in prostate cancer, from Clinical Care Options (CCO)

Charles J. Ryan, MD Released: July 2, 2021

Downloadable PDF with highlights from a CCO podcast on PARP inhibitors and emerging combination strategies in prostate cancer.

Charles J. Ryan, MD
Program Director
person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD
Released: June 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue